# F-star Therapeutics, Inc.

F-star Therapeutics, Inc. is a company headquartered in Cambridge, United Kingdom.

## Company overview

- **Legal name:** F-star Therapeutics, Inc.
- **Former names in filing history:** Spring Bank Pharmaceuticals, Inc. (2013-01-25 to 2020-11-09)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Cambridge, United Kingdom
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001566373

## About

F-star Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001566373, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2022-03-15, it reported annual revenue of USD 21,167,000; net income of USD -31,283,000; total assets of USD 123,021,000 for the fiscal period ended 2021-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $21.2M (USD 21,167,000)
- **Net income:** -$31.3M (USD -31,283,000)
- **Total assets:** $123.0M (USD 123,021,000)
- **Cash and equivalents:** $78.5M (USD 78,549,000)
- **Operating cash flow:** -$27.3M (USD -27,267,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $11.3M (USD 11,256,000)
- **Net income:** -$25.6M (USD -25,619,000)
- **Total assets:** $63.6M (USD 63,609,000)
- **Cash and equivalents:** $18.5M (USD 18,526,000)
- **Operating cash flow:** -$16.2M (USD -16,226,000)

### FY2019 (period ended 2019-12-31)

- **Net income:** -$24.1M (USD -24,097,000)
- **Total assets:** $63.2M (USD 63,197,000)
- **Cash and equivalents:** $28.7M (USD 28,709,000)
- **Operating cash flow:** -$29.1M (USD -29,055,000)
- **Later filings:** Net income, Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2018 (period ended 2018-12-31)

- **Net income:** -$22.9M (USD -22,854,000)
- **Total assets:** $68.8M (USD 68,811,000)
- **Cash and equivalents:** $14.7M (USD 14,724,000)
- **Operating cash flow:** -$25.2M (USD -25,244,000)

## Recent SEC filings

- Form SC 13G — filed 2023-03-17
- Form 8-K — filed 2023-03-09 — period 2023-03-08 — 8-K
- Form 8-K — filed 2023-03-07 — period 2023-03-07 — 8-K
- Form 8-K — filed 2023-03-06 — period 2023-03-06 — 8-K
- Form 8-K — filed 2023-02-23 — period 2023-02-22 — 8-K
- Form 8-K — filed 2023-02-09 — period 2023-02-09 — 8-K
- Form 8-K — filed 2023-02-01 — period 2023-01-31 — 8-K
- Form 8-K — filed 2022-12-30 — period 2022-12-30 — 8-K
- Form 8-K — filed 2022-12-29 — period 2022-12-29 — 8-K
- Form 8-K — filed 2022-12-21 — period 2022-12-20 — 8-K
- Form 8-K — filed 2022-12-19 — period 2022-12-19 — 8-K
- Form 8-K — filed 2022-11-21 — period 2022-11-20 — 8-K

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/f-star-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology